UBS Group Issues Pessimistic Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR) had its price objective cut by research analysts at UBS Group from $72.00 to $70.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price target points to a potential upside of 135.29% from the company’s previous close.

KYMR has been the subject of a number of other reports. Citigroup began coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $52.00 target price for the company. HC Wainwright boosted their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Guggenheim restated a “buy” rating and set a $52.00 target price on shares of Kymera Therapeutics in a research report on Monday. Stephens reiterated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, Bank of America decreased their price objective on shares of Kymera Therapeutics from $47.00 to $44.00 and set a “neutral” rating for the company in a research report on Monday. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.27.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $29.75 on Tuesday. The firm has a market capitalization of $1.94 billion, a PE ratio of -12.71 and a beta of 2.18. Kymera Therapeutics has a 1-year low of $19.45 and a 1-year high of $53.27. The company’s fifty day moving average price is $29.48 and its 200-day moving average price is $37.31.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business’s quarterly revenue was up 114.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.69) earnings per share. As a group, research analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. This represents a 2.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This represents a 2.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,659 shares of company stock worth $324,567 in the last 90 days. Insiders own 16.01% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its stake in Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after acquiring an additional 95,547 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Kymera Therapeutics by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company’s stock valued at $15,577,000 after acquiring an additional 20,346 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Kymera Therapeutics by 174.2% in the 4th quarter. Victory Capital Management Inc. now owns 19,899 shares of the company’s stock valued at $801,000 after buying an additional 12,643 shares during the period. Wells Fargo & Company MN grew its stake in shares of Kymera Therapeutics by 51.8% in the 4th quarter. Wells Fargo & Company MN now owns 21,939 shares of the company’s stock valued at $883,000 after buying an additional 7,487 shares during the period. Finally, Teacher Retirement System of Texas grew its stake in shares of Kymera Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 11,490 shares of the company’s stock valued at $462,000 after buying an additional 3,026 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.